Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
نویسندگان
چکیده
منابع مشابه
Discovering what makes STAT signaling TYK in T-ALL.
SUMMARY RNA interference screening establishes TYK2 dependence in T-cell acute lymphoblastic leukemia (T-ALL), leading to identification of TYK2-activating mutations and increased IL-10 receptor signaling in T-ALL cell lines. Cancer Discov; 3(5); 494-6. ©2013 AACR.
متن کاملDETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)
Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...
متن کاملMicroRNAs as a New Molecular Biomarker for Diagnosis and Prognosis of T-cell Acute Lymphoblastic Leukemia (T-ALL): A Systematic Review
MicroRNAs (miRNAs, miRs) are small endogenous non-coding RNAs that regulate the expression of protein-encoding genes at the post-transcriptional level. Several studies have described the role of miRNAs in T-cell acute lymphoblastic leukemia (T-ALL), including tumor suppressor and oncogenic miRNAs. Down-regulation of miRNA expression is a prominent feature of human malignancy. This down-regulati...
متن کاملdetermination of a shared epitope on cells from acute myelogenic leukemia (aml) and t-acute lymphoblastic leukemia ( t-all)
two igm monoclonal antibodies (mab) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing balbi c mice with a histiocytic cell line (uy37). these two mabs (designated as 6c9 and 4c4) reacted with blast cells of t-acute lymphoblastic leukemia (t-all) and acute myelogenous leukemia (aml) patients as well as leukemic cells from patients...
متن کاملTherapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
T-ALL patients treated with intensive chemotherapy achieve high rates of remission. However, frequent long-term toxicities and relapses into chemotherapy-refractory tumors constitute major clinical challenges which could be met by targeted therapies. c-MYC is a central oncogene in T-ALL, prompting the exploration of the efficacy of MYC inhibitors such as JQ1 (BET-bromodomain inhibitor), and SAH...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2017
ISSN: 0007-1048
DOI: 10.1111/bjh.14559